2004-2008, Quantum Laboratories, Inc.. All rights reserved.




Protocol CN138012-016: A Randomized, Double Blind Comparison of the efficacy and Safety of Aripiprazole Intramuscular Formula, Haloperidol, or Placebo in the treatment of Acutely Agitated Patients with a Diagnosis of Schizophrenia or Schizoaffective Disorder.

Protocol 041509: A Double blind, Long Term extension trial to asses the efficacy and Safety of qd and bid dose regimes of up to 30 mg / day Org 5222 (Asenapine) in subjects with Schizophrenia.

Protocol 041019: A 6 week, multicenter, double blind, randomized, placebo controlled trial to asses the efficacy and Safety of qd and bid dose regimes of up to 30 mg / day Org 5222 (Asenapine) versus placebo in subjects suffering from an acute exacerbation of Schizophrenia.

PROTOCOL R076477-SCH-305: A Randomized, Double Blind Placebo Controlled Parallel Group, Dose Response Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended Release OROS (R) Paliperidone (3, 9, and 15 mg) and Olanzepine (10mg) in the Treatment of Subjects with Schizophrenia

Protocol AZ 5077IL/0089 (Clears Trial) A Multicenter, open label, flexible dose, parallel group evaluation of the cataractogenic potential of Quetiapine fumarate (SEROQUEL TM ) and Risperidone (RISPERDAL TM ) in the long term treatment of patients with Schizophrenia and Schizoaffective Disorder.



For more information please call (561) 687-2111


Our facility identifies and recruits appropriate patients and monitors them during the study. If you qualify and consent to participate, there will be no charge for your study medication and office visits. Additionally, you are responsible for attendence to regular scheduled appointments.


During any one-year period, up to 50 million Americans suffer from clearly diagnosable mental disorder involving a degree of incapacity that interferes with employment, attendence at school or daily life.